Concepedia

Davit Giorgadze

DG

Statistics

Publications

5

Citations

899

H-Index

5

Active since

2021

Affiliations

Budgetary Healthcare Institution of Omsk Region Regional Clinical Hospital(Current)

David Tvildiani Medical University

Tbilisi State Medical University

Regeneron (United States)

Polish Mother’s Memorial Hospital Research Institute

Davit Giorgadze is an author at Budgetary Healthcare Institution of Omsk Region Regional Clinical Hospital specializing in oncology, medicine, and chemotherapy.

Publications per year

2021–2023

5

Publications

5

Effect of First-Line Serplulimab vs Placebo Added to Chemotherapy on Survival in Patients With Extensive-Stage Small Cell Lung Cancer

Ying Cheng, Liang Han, Lin Wu et al. · JAMA · 2022 · 456 citations · Full text

, , +17

Cemiplimab plus chemotherapy versus chemotherapy alone in non-small cell lung cancer: a randomized, controlled, double-blind phase 3 trial

Miranda Gogishvili, Tamar Melkadze, Tamta Makharadze et al. · Nature Medicine · 2022 · 301 citations · Full text

, , +15

Cemiplimab Plus Chemotherapy Versus Chemotherapy Alone in Advanced NSCLC: 2-Year Follow-Up From the Phase 3 EMPOWER-Lung 3 Part 2 Trial

Tamta Makharadze, Miranda Gogishvili, Tamar Melkadze et al. · Journal of Thoracic Oncology · 2023 · 98 citations · Full text

, , +15

Efficacy, Safety and Immunogenicity of MB02 (Bevacizumab Biosimilar) versus Reference Bevacizumab in Advanced Non-Small Cell Lung Cancer: A Randomized, Double-Blind, Phase III Study (STELLA)

Dmytro Trukhin, Elena Poddubskaya, Zoran Andrić et al. · BioDrugs · 2021 · 28 citations · Full text

, , +14

Quality of life with cemiplimab plus chemotherapy for first‐line treatment of advanced non–small cell lung cancer: Patient‐reported outcomes from phase 3 EMPOWER‐Lung 3

Tamta Makharadze, Ruben G.W. Quek, Tamar Melkadze et al. · Cancer · 2023 · 16 citations · Full text

, , +15

1–5 of 5